NOVO.B.DK

228.9

-1.23%↓

GMAB.DK

1,698

+2.01%↑

HLUNB.DK

38.76

+1.73%↑

ZEAL.DK

286.2

-1.65%↓

AMBUB.DK

68

-1.88%↓

NOVO.B.DK

228.9

-1.23%↓

GMAB.DK

1,698

+2.01%↑

HLUNB.DK

38.76

+1.73%↑

ZEAL.DK

286.2

-1.65%↓

AMBUB.DK

68

-1.88%↓

NOVO.B.DK

228.9

-1.23%↓

GMAB.DK

1,698

+2.01%↑

HLUNB.DK

38.76

+1.73%↑

ZEAL.DK

286.2

-1.65%↓

AMBUB.DK

68

-1.88%↓

NOVO.B.DK

228.9

-1.23%↓

GMAB.DK

1,698

+2.01%↑

HLUNB.DK

38.76

+1.73%↑

ZEAL.DK

286.2

-1.65%↓

AMBUB.DK

68

-1.88%↓

NOVO.B.DK

228.9

-1.23%↓

GMAB.DK

1,698

+2.01%↑

HLUNB.DK

38.76

+1.73%↑

ZEAL.DK

286.2

-1.65%↓

AMBUB.DK

68

-1.88%↓

Search

Coloplast A-S (Class B)

Atvērts

436.4 1.23

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

430.2

Max

439.7

Galvenie mērījumi

By Trading Economics

Ienākumi

522M

1.4B

Pārdošana

83M

7B

P/E

Sektora vidējais

24.382

57.05

EPS

6.32

Dividenžu ienesīgums

5.47

Peļņas marža

19.835

Darbinieki

16,983

EBITDA

309M

2.3B

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

+11.86% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

5.47%

2.52%

Nākamie ieņēmumi

2026. g. 12. maijs

Nākamais dividenžu datums

2026. g. 20. maijs

Nākamais Ex dividenžu datums

2026. g. 18. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-21B

97B

Iepriekšējā atvēršanas cena

435.17

Iepriekšējā slēgšanas cena

436.4

Coloplast A-S (Class B) Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 26. marts 23:43 UTC

Tirgus saruna

Nikkei May Decline Amid Uncertainty Over Iran Peace Talks -- Market Talk

2026. g. 26. marts 23:36 UTC

Tirgus saruna
Galvenie ziņu notikumi

Gold Rises Amid Signs of Easing Middle East Tensions -- Market Talk

2026. g. 26. marts 23:35 UTC

Iegādes, apvienošanās, pārņemšana

Pernod Ricard: Confirms Discussions With Brown-Forman

2026. g. 26. marts 23:29 UTC

Peļņas

Haier Smart Home: Company to Finance Share Buybacks Via Internal Funds >600690.SH

2026. g. 26. marts 23:28 UTC

Peļņas

Haier Smart Home Plans A Share Buybacks of CNY3.0B-CNY6.0B >600690.SH

2026. g. 26. marts 23:28 UTC

Peļņas

Haier Smart Home Plans to Increase Payout Ratio to 60% for 2027, 2028 >600690.SH

2026. g. 26. marts 23:28 UTC

Peļņas

Haier Smart Home Plans Cash Dividend Payout Ratio of Up to 58% for 2026 >600690.SH

2026. g. 26. marts 23:27 UTC

Peļņas

Haier Smart Home 2025 Net CNY19.55B Vs. Net CNY18.73B >600690.SH

2026. g. 26. marts 23:27 UTC

Peļņas

Haier Smart Home 2025 Rev CNY302.33B Vs. CNY286.01B >600690.SH

2026. g. 26. marts 23:08 UTC

Tirgus saruna

Infratil's Investor Day Addresses Data-Center Issues -- Market Talk

2026. g. 26. marts 23:04 UTC

Iegādes, apvienošanās, pārņemšana

Pernod Ricard in Talks to Combine With Jack Daniel's Maker Brown-Forman -- WSJ

2026. g. 26. marts 23:04 UTC

Iegādes, apvienošanās, pārņemšana

Families Behind Pernod, Brown-Forman Would Each Likely Retain Significant Stakes, Source Says -- WSJ

2026. g. 26. marts 23:04 UTC

Iegādes, apvienošanās, pārņemšana

Pernod, Brown-Forman Discussing Mostly Stock Deal, Source Says -- WSJ

2026. g. 26. marts 23:04 UTC

Iegādes, apvienošanās, pārņemšana

Pernod-Brown-Forman Deal Announcement Could Be Weeks Away, Sources Say -- WSJ

2026. g. 26. marts 23:04 UTC

Iegādes, apvienošanās, pārņemšana

Pernod in Deal Talks With Brown-Forman -- WSJ

2026. g. 26. marts 22:41 UTC

Iegādes, apvienošanās, pārņemšana

Brown-Forman: No Agreement Has Been Reached as to Terms of Any Possible Pernod Ricard Transaction

2026. g. 26. marts 22:41 UTC

Iegādes, apvienošanās, pārņemšana

Brown-Forman: Synergies From Contemplated Pernod Ricard Combination Expected to Be Significant

2026. g. 26. marts 22:26 UTC

Peļņas

Jiangxi Copper 2025 Rev CNY544.62B Vs. CNY516.61B >0358.HK

2026. g. 26. marts 22:26 UTC

Peļņas

Jiangxi Copper 2025 Net CNY7.13B Vs. Net CNY6.96B >0358.HK

2026. g. 26. marts 22:26 UTC

Peļņas

Jiangxi Copper Higher Demand For Products Supported Results>0358.HK

2026. g. 26. marts 22:08 UTC

Peļņas

Air China 2025 Loss CNY1.79B Vs. Loss CNY232.56M >0753.HK

2026. g. 26. marts 22:08 UTC

Peļņas

Air China Impairment Loss on Goodwill Weighed on Results>0753.HK

2026. g. 26. marts 22:08 UTC

Peļņas

Air China 2025 Rev CNY171.48B Vs. CNY166.70B >0753.HK

2026. g. 26. marts 22:07 UTC

Tirgus saruna
Galvenie ziņu notikumi

Global Energy Roundup: Market Talk

2026. g. 26. marts 22:07 UTC

Tirgus saruna
Galvenie ziņu notikumi

Open-Pit Gold Miners Most Exposed to High Fuel Prices -- Market Talk

2026. g. 26. marts 22:00 UTC

Peļņas

Tsingtao Brewery 2025 Net CNY4.59B Vs. Net CNY4.34B >0168.HK

2026. g. 26. marts 22:00 UTC

Peļņas

Tsingtao Brewery: Higher Volume Sales of Beer Supported Results>0168.HK

2026. g. 26. marts 22:00 UTC

Peļņas

Tsingtao Brewery 2025 Rev CNY32.47B Vs. CNY32.14B >0168.HK

2026. g. 26. marts 21:39 UTC

Iegādes, apvienošanās, pārņemšana

BlueScope: Sees Early Indications of Strong Interest in Site Adjacent Western Port

2026. g. 26. marts 21:38 UTC

Iegādes, apvienošanās, pārņemšana

BlueScope: Has Begun Expression of Interest Process For 65-Hectare Site Adjacent Western Port

Salīdzinājums

Cenas izmaiņa

Coloplast A-S (Class B) Prognoze

Cenas mērķis

By TipRanks

11.86% augšup

Prognoze 12 mēnešiem

Vidējais 901.38 DKK  11.86%

Augstākais 1,056 DKK

Zemākais 720 DKK

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Coloplast A-S (Class B) — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

8 ratings

2

Pirkt

4

Turēt

2

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat